US HB7050

Creates a distinct regulatory pathway for homeopathic drug products under the Federal Food, Drug, and Cosmetic Act, exempting them from standard drug approval requirements including premarket FDA approval

Defines homeopathic drug products as those containing only homeopathic ingredients listed in the Homeopathic Pharmacopoeia of the United States or prepared according to recognized homeopathic standards

Requires retail homeopathic products to include indications for "self-limiting conditions" supported by traditional homeopathic references, peer-reviewed journals, or clinical usage documentation, along with a disclaimer stating the FDA has not evaluated the indications

Establishes a 10-member Homeopathic Drug Product Advisory Committee to advise the FDA, including representatives from consumer organizations, manufacturers, licensed practitioners, and the Homeopathic Pharmacopoeia Convention

Withdraws the FDA's December 2022 guidance on homeopathic products and prohibits private lawsuits for false advertising based on lack of clinical trials to substantiate homeopathic product claims